'Positron Emitting Activity', 'Glucagon-like Peptide-1 (GLP-1) Agonists', 'Interleukin-17A Antagonists', 'Norepinephrine Uptake Inhibitors', 'Serotonin Uptake Inhibitors', 'Janus Kinase Inhibitors', 'Selective Estrogen Receptor Modulators', 'Phosphodiesterase 5 Inhibitors', 'Kinase Inhibitors', 'P2Y12 Receptor Antagonists', 'Nucleic Acid Synthesis Inhibitors', 'Folic Acid Metabolism Inhibitors', 'VEGFR2 Inhibitors', 'HER1 Antagonists', 'P-Glycoprotein Inhibitors', 'Organic Anion Transporting Polypeptide 1B1 Inhibitors', 'Organic Anion Transporting Polypeptide 1B3 Inhibitors', 'Breast Cancer Resistance Protein Inhibitors', 'Corticosteroid Hormone Receptor Agonists', 'CD80-directed Antibody Interactions', 'CD86-directed Antibody Interactions', 'Protein Kinase Inhibitors', 'Cytochrome P450 3A4 Inhibitors', 'Factor Xa Inhibitors', 'Nucleoside Reverse Transcriptase Inhibitors', 'SLAMF7-directed Antibody Interactions', 'CTLA-4-directed Antibody Interactions', 'HIV Protease Inhibitors', 'UGT1A1 Inhibitors', 'UDP Glucuronosyltransferases Inhibitors', 'Cytochrome P450 3A Inhibitors', 'Cytochrome P450 2C8 Inhibitors', 'Cytochrome P450 2D6 Inhibitors', 'Programmed Death Receptor-1-directed Antibody Interactions', 'Hydroxymethylglutaryl-CoA Reductase Inhibitors', 'DNA Polymerase Inhibitors', 'Orexin Receptor Antagonists', 'Angiotensin-converting Enzyme Inhibitors', '5-alpha Reductase Inhibitors', 'Dipeptidyl Peptidase 4 Inhibitors', 'HIV Integrase Inhibitors', 'Serotonin 1b Receptor Agonists', 'Serotonin 1d Receptor Agonists', 'Neurokinin 1 Antagonists', 'Cytochrome P450 2C9 Inducers', 'Cytochrome P450 3A4 Inducers', 'Histone Deacetylase Inhibitors', 'Angiotensin 2 Receptor Antagonists', 'Leukotriene Receptor Antagonists', 'Non-Nucleoside Reverse Transcriptase Inhibitors', 'HCV NS3/4A Protease Inhibitors', 'DNA Terminase Complex Inhibitors', 'Cytochrome P450 2C19 Inducers', 'Dipeptidase Inhibitors', 'Tumor Necrosis Factor Receptor Blocking Activity', 'HER2/Neu/cerbB2 Antagonists', 'Adrenergic alpha-Antagonists', 'Adrenergic beta1-Antagonists', 'Adrenergic beta2-Antagonists', 'Dopamine Agonists', 'CD22-directed Antibody Interactions', 'Proton Pump Inhibitors', 'mTOR Inhibitors', 'Estrogen Receptor Agonists', 'CD33-directed Antibody Interactions', 'Androgen Receptor Agonists', 'Bile-acid Binding Activity', 'Prostaglandin Receptor Agonists', 'Cholinergic Muscarinic Antagonists', 'alpha Glucosidase Inhibitors', 'Topoisomerase Inhibitors', 'Antibody-Surface Protein Interactions', 'Aromatase Inhibitors', 'Alkylating Activity', 'X-Ray Contrast Activity', 'Osmotic Activity', 'Acetylcholine Release Inhibitors', 'Cyclooxygenase Inhibitors', 'Histamine H1 Receptor Antagonists', 'Adrenergic beta-Antagonists', 'Decarboxylase Inhibitors', 'Calcineurin Inhibitors', 'Opioid Agonists', 'Full Opioid Agonists', 'Phosphate Chelating Activity', 'Dihydrofolate Reductase Inhibitors', 'Organic Cation Transporter 2 Inhibitors', 'Adrenergic alpha-Agonists', 'Adrenergic Agonists', 'GABA A Agonists', 'Vascular Endothelial Growth Factor Inhibitors', 'PCSK9 Inhibitors', 'Interleukin 6 Receptor Antagonists', 'Interleukin 4 Receptor alpha Antagonists', 'Cholinergic Antagonists', 'Gonadotropin Releasing Hormone Receptor Agonists', 'Aldosterone Antagonists', 'Calcium Channel Antagonists', 'RNA Synthetase Inhibitors', 'Oxidation-Reduction Activity', 'beta Lactamase Inhibitors', 'Cytochrome P450 2C19 Inhibitors', 'Cytochrome P450 2C9 Inhibitors', 'Gonadotropin Releasing Hormone Receptor Antagonists', 'Phosphodiesterase 3 Inhibitors', 'Serotonin 3 Receptor Antagonists', 'Cholinesterase Inhibitors', 'Partial Opioid Agonists', 'Opioid Antagonists', 'Cholinergic Muscarinic Agonists', 'Acetyl Aldehyde Dehydrogenase Inhibitors', 'Cytochrome P450 3A Inducers', 'Cytochrome P450 1A2 Inducers', 'Cytochrome P450 2B6 Inducers', 'UDP Glucuronosyltransferases Inducers', 'Xanthine Oxidase Inhibitors', 'Vesicular Monoamine Transporter 2 Inhibitors', 'Endothelin Receptor Antagonists', 'Competitive Opioid Antagonists', 'Vitamin K Inhibitors', 'Cholinergic Agonists', 'Dyes', 'Carbonic Anhydrase Inhibitors', 'Adrenergic alpha1-Agonists', 'Magnesium Ion Exchange Activity', 'Receptor Tyrosine Kinase Inhibitors', 'CD20-directed Antibody Interactions', 'Poly(ADP-Ribose) Polymerase Inhibitors', 'Smoothened Receptor Antagonists', 'Vascular Endothelial Growth Factor-directed Antibody Interactions', 'Partial Cholinergic Nicotinic Agonists', 'Antigen Neutralization', 'Histamine Receptor Antagonists', 'Cytochrome P450 2C8 Inducers', 'Cytochrome P450 2D6 Inducers', 'Cytochrome P450 2B6 Inhibitors', 'Organic Cation Transporter 1 Inhibitors', 'Monoamine Oxidase Inhibitors', 'Peroxisome Proliferator-activated Receptor alpha Agonists', 'Surfactant Activity', 'Cytochrome P450 1A2 Inhibitors', 'Somatostatin Receptor Agonists', 'Catechol O-Methyltransferase Inhibitors', 'Interleukin 2 Receptor Antagonists', 'Interleukin 2 Receptor-directed Antibody Interactions', 'Potassium Channel Antagonists', 'Iron Chelating Activity', 'Sphingosine 1-Phosphate Receptor Modulators', 'Neprilysin Inhibitors', 'Organic Anion Transporter 1 Inhibitors', 'Organic Anion Transporter 3 Inhibitors', 'Thrombopoietin Receptor Agonists', 'UGT1A3 Inhibitors', 'UGT1A4 Inhibitors', 'UGT1A6 Inhibitors', 'UGT1A9 Inhibitors', 'UGT2B7 Inhibitors', 'UGT2B15 Inhibitors', 'Tyrosine Kinase Inhibitors', 'CD19 Receptor Interactions', 'Thrombin Inhibitors', 'Adrenergic beta2-Agonists', 'Cytochrome P450 17A1 Inhibitors', 'Dopamine D2 Antagonists', 'Bradykinin B2 Receptor Antagonists', 'Cytochrome P450 3A5 Inhibitors', 'Adrenergic alpha2-Agonists', 'Adrenergic beta-Agonists', 'Peroxisome Proliferator-activated Receptor Activity', 'Histamine H2 Receptor Antagonists', 'GABA B Agonists', 'Cytochrome P450 1A Inducers', 'M2 Protein Inhibitors', 'Dopamine Uptake Inhibitors', 'Acidifying Activity', 'Calcium Chelating Activity', 'NMDA Receptor Antagonists', 'P-Glycoprotein Interactions', 'Interferon Inducers', 'Protein Synthesis Inhibitors', 'Neuraminidase Inhibitors', 'Interleukin-5 Antagonists', 'Cystine Disulfide Reduction', 'Thyroid Hormone Synthesis Inhibitors', 'Phenylalanine Hydroxylase Activators', 'Interleukin 17 Receptor A Antagonists', 'Ammonium Ion Binding Activity', 'Monoamine Oxidase-B Inhibitors', 'Photoabsorption', 'Metal Chelating Activity', 'Hydroxyphenylpyruvate Dioxygenase Inhibitors', 'Radiopharmaceutical Activity', 'Magnetic Resonance Contrast Activity', 'Melanin Synthesis Inhibitors', 'Phosphodiesterase 4 Inhibitors', 'Estrogen Receptor Antagonists', 'Interleukin 5 Receptor alpha-directed Antibody Interactions', 'Programmed Death Ligand-1 Antagonists', 'Programmed Death Ligand-1-directed Antibody Interactions', 'Sodium-Glucose Transporter 2 Inhibitors', 'Amylin Agonists', 'Irrigation', 'P-Glycoprotein Inducers', 'Increased Calcium-sensing Receptor Sensitivity', 'Ultrasound Contrast Activity', 'Adenosine Receptor Agonists', 'Reduction Activity', 'Guanylate Cyclase Activators', 'Androgen Receptor Antagonists', 'Adrenergic beta3-Agonists', 'Serotonin 4 Receptor Antagonists', 'Uncompetitive NMDA Receptor Antagonists', 'Sigma-1 Receptor Agonists', 'Endogenous Antigen Neutralization', 'Melatonin Receptor Agonists', 'Trypsin Inhibitors', '5-Lipoxygenase Inhibitors', 'Glucosylceramide Synthase Inhibitors', 'Cholinesterase Reactivators', 'Virus Neutralization', 'N-Calcium Channel Receptor Antagonists', 'Demulcent Activity', 'Catecholamine Synthesis Inhibitors', 'Complement Inhibitors', 'Chloride Channel Activators', 'Kallikrein Inhibitors', 'Progestational Hormone Receptor Antagonists', 'Proteasome Inhibitors', 'Sclerosing Activity', 'Interleukin-23 Antagonists', 'B Lymphocyte Stimulator-directed Antibody Interactions', 'Anthrax Protective Antigen-directed Antibody Interactions', 'Chemokine Co-receptor 5 Antagonists', 'Multidrug and Toxin Extrusion Transporter 1 Inhibitors', 'Renin Inhibitors', 'Selective Progesterone Receptor Modulators', 'IgE-directed Antibody Interactions', 'Polymerase Acidic Endonuclease Inhibitors', 'Chelating Activity', 'alpha-Particle Emitting Activity', 'Guanylate Cyclase Stimulators', 'Tropomyosin Receptor Kinases Inhibitors', 'Epoxide Hydrolase Inhibitors', 'Venom Neutralization', 'CD30-directed Antibody Interactions', 'Chloride Channel Activation Potentiators', 'Heparin Binding Activity', 'Carbamoyl Phosphate Synthetase 1 Activators', 'Methylating Activity', 'Potassium Ion Binding Activity', 'Lymphocyte Function-Associated Antigen-1 Antagonists', 'Lead Chelating Activity', 'RANK Ligand Blocking Activity', 'Hyperpolarization-activated Cyclic Nucleotide-gated Channel Antagonists', 'Interleukin-12 Antagonists', 'Interleukin-6 Antagonists', 'CD38-directed Antibody Interactions', 'Ion Exchange Activity', 'CD52-directed Antibody Interactions', 'Dihydroorotate Dehydrogenase Inhibitors', 'Vasopressin V2 Receptor Antagonists', 'Isocitrate Dehydrogenase 2 Inhibitors', 'Fusion Protein Inhibitors', 'Angiotensin 2 Type 1 Receptor Antagonists', 'Lipase Inhibitors', 'Opioid mu-Receptor Agonists', 'RNA Replicase Inhibitors', 'Organic Anion Transporting Polypeptide 2B1 Inhibitors', 'AMPA Receptor Antagonists', 'Serotonin 2c Receptor Agonists', 'Integrin Receptor Antagonists', 'Thymidine Phosphorylase Inhibitors', 'Prostacyclin Receptor Agonists', 'Free Radical Scavenging Activity', 'Vasopressin Receptor Antagonists', 'Glycolipid Disialoganglioside-directed Antibody Interactions', 'Interleukin 1 Receptor Antagonists', 'Interferon gamma Antagonists', 'Bacterial Neurotoxin Neutralization', 'Glucagon-like Peptide-2 (GLP-2) Agonists', 'Farnesoid X Receptor Agonists', 'Tryptophan Hydroxylase Inhibitors', 'Protease-activated Receptor-1 Antagonists', 'Rho Kinase Inhibitors', 'Urate Transporter 1 Inhibitors', 'Growth Hormone Secretagogue Receptor Agonists', 'CD123 Interactions', 'Adrenal Steroid Synthesis Inhibitors', 'Microsomal Triglyceride Transfer Protein Inhibitors', 